CM

I-Tek Medical and Vita Group Join Forces to Create VitaTek: The Only Vertically Integrated Medical Device Company

Retrieved on: 
Wednesday, November 8, 2023
Medical Devices, Other Health, Health, Professional Services, Other Professional Services, CM, Vita Group Limited, R, Multimedia, Communication, Sterilization, Medical device

A first for the medical device development industry, I-Tek Medical , a Minneapolis, Minnesota based medical device contract manufacturing company, has joined forces with Vita Group , a leading medical device incubator and accelerator, also in Minneapolis, to establish the only vertically integrated medical device company in the United States, VitaTek.

Key Points: 
  • A first for the medical device development industry, I-Tek Medical , a Minneapolis, Minnesota based medical device contract manufacturing company, has joined forces with Vita Group , a leading medical device incubator and accelerator, also in Minneapolis, to establish the only vertically integrated medical device company in the United States, VitaTek.
  • View the full release here: https://www.businesswire.com/news/home/20231108776170/en/
    Founded in 2005, I-Tek Medical is an industry leader in contract design development and manufacturing services.
  • "With the merger with Vita Group completed, we're not just redefining the future; we're rewriting the entire playbook.
  • Their dedication to delivering a seamless, comprehensive experience to partners, customers, and investors underscores their commitment to reshaping the future of medical device development.

Boxlight Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Software, Audio, Video, Other Education, Consumer Electronics, Technology, Primary, Secondary, Education, Other Technology, Adjustment, Nine Months, Working capital, CM, ELB, Cleverlance Enterprise Solutions, Three Months, EBITDA, EPS, Corporation, Mimio, Cryptocurrency, Security (finance), Video game, Clothing, Holding company, Insurance

Boxlight Corporation (Nasdaq: BOXL) (“Boxlight” or the “Company”), a leading provider of interactive technology solutions, today announced the Company’s financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Boxlight Corporation (Nasdaq: BOXL) (“Boxlight” or the “Company”), a leading provider of interactive technology solutions, today announced the Company’s financial results for the third quarter ended September 30, 2023.
  • For the fourth quarter, we expect revenue and Adjusted EBITDA to be in line with the fourth quarter of 2022.
  • EBITDA loss for the nine months ended September 30, 2023 was $3.0 million, as compared to $12.9 million EBITDA for the nine months ended September 30, 2022.
  • The Company will hold a conference call to announce its third quarter 2023 financial results on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Wednesday, November 8, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

Retrieved on: 
Tuesday, November 7, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Symantec Endpoint Protection, News, Patisiran, Law, CRL, ALNY, New Drug Application, Vincent Wong, Amyloidosis, Crown Law Office (New Zealand), Patient, Shanda, Pharmaceutical industry, Alnylam Pharmaceuticals

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:

Key Points: 
  • NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities fraud.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • If you suffered a loss on your investment in Alnylam, contact us about potential recovery by using the link below.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Monday, November 6, 2023
FDA, CM, Food, ATTR, Alnylam Pharmaceuticals, Cardiomyopathy, Telephone, Symantec Endpoint Protection, News, Patisiran, CRL, Levi, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Thursday, November 2, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Wednesday, November 1, 2023
FDA, CM, Food, ATTR, Alnylam Pharmaceuticals, Cardiomyopathy, Telephone, Symantec Endpoint Protection, News, Patisiran, CRL, Levi, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

Retrieved on: 
Tuesday, October 31, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Symantec Endpoint Protection, News, Patisiran, Law, CRL, ALNY, New Drug Application, Vincent Wong, Amyloidosis, Crown Law Office (New Zealand), Patient, Shanda, Pharmaceutical industry, Alnylam Pharmaceuticals

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:

Key Points: 
  • NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities fraud.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • If you suffered a loss on your investment in Alnylam, contact us about potential recovery by using the link below.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Monday, October 30, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)

Retrieved on: 
Friday, October 27, 2023
FDA, CM, Food, ATTR, Alnylam Pharmaceuticals, Cardiomyopathy, Telephone, Symantec Endpoint Protection, News, Patisiran, CRL, Levi, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.